Baird Reiterates an 'Outperform' on Alexion Pharmaceuticals (ALXN); Raising N-T Estimates Ahead of Qtr

Baird reiterates an 'Outperform' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $110.00 (from $100.00).

Analyst, Christopher Raymond, said, "While management provided detailed color around Q212 last quarter, we think the operational flexibility of this business model, coupled with real revenue upside potential from the ongoing Soliris aHUS launch can make for yet another quarterly beat. As such, we are raising our Q212 EPS estimate to $0.38 from $0.35...Despite a higher-than-average valuation, we think this name can continue to work higher."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $97.19 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Va Tech Wabag Ltd. (VATW:IN) PT Raised to INR2,410 at ICICI Securities
• Sansera Engineering Ltd (SANSERA:IN) PT Raised to INR4,250 at ICICI Securities